Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Status:
Active, not recruiting
Trial end date:
2020-03-01
Target enrollment:
Participant gender:
Summary
Phase II trial of induction immunotherapy with atezolizumab for patients with unresectable
stage IIIA and IIIB NSCLC eligible for chemoradiotherapy with curative intent.